Research advances in immune checkpoint inhibitor-related cholangitis / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 463-468, 2023.
Article
Dans Chinois
| WPRIM
| ID: wpr-964816
ABSTRACT
Immune checkpoint inhibitors (ICIs) have ushered in a new era of tumor treatment; however, immunotherapy-related adverse events are critical issues that restrict the clinical application of ICIs and have attracted wide attention. The liver is one of the target organs that is easily affected. With the progress in research, scholars have found that besides hepatocytes, intrahepatic and extrahepatic bile ducts can also be attacked by the immune system, leading to the disease known as immune-related cholangitis. This article reviews the research advances in ICI-related cholangitis by summarizing related articles, in order to preliminarily reveal its clinical, pathological, and imaging features and provide clues for early identification, standard treatment, and subsequent research.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Journal of Clinical Hepatology
Année:
2023
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS